Oncocyte Presents New Data at AACR

Rhea-AI Summary

Oncocyte Corporation (Nasdaq: OCX) has unveiled five original research posters at the American Association for Cancer Research Annual Meeting. Four of these highlight the tumor microenvironment's role in therapeutic responses, utilizing DetermaIO technology. A fifth poster presents promising results of DetermaCNI, a blood test focused on metastatic pancreatic cancer treatment monitoring. CEO Joshua Riggs emphasized DetermaIO's potential in identifying patients suited for immunotherapies and DetermaCNI's blood-only approach, making it a preferred choice for tissue conservation. Oncocyte specializes in precision diagnostics, with notable products including DetermaIO and the pipeline test DetermaCNI.

Positive

• Five original research posters presented at a key cancer research conference.
• DetermaIO shows strong potential in identifying patients likely to respond to immunotherapies.
• DetermaCNI offers a convenient blood-only solution for monitoring therapy efficacy in metastatic pancreatic cancer.

Negative

• None.

IRVINE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that five posters of original research are being presented at the Annual Meeting of the American Association for Cancer Research. Four abstracts explore the tumor microenvironment and its potential implications for therapeutic response, leveraging expertise and technology behind DetermaIO. A fifth poster highlights exciting study results applying DetermaCNI, Oncocyte’s proprietary therapeutic monitoring blood test, to metastatic pancreatic cancer.

1. Cronister, et al. “Methylation as a surrogate for mutations to identify therapeutic targets”
2. Seitz, et al. “Using tumor immune microenvironment physiologic profiling to tailor immune checkpoint inhibitor diagnostic classification”
3. Cronister, et al. “The role of microRNAs in the tumor immune microenvironment”
4. Ring, et al. “In Silico dissection of immune infiltrate signatures that are detected by DetermaIO, a predictor of response to immune therapy”
5. Cannas, et al. “Liquid biopsy signature combining copy number instability and mutant KRAS detection is associated with survival for patients with metastatic pancreatic cancer”

“DetermaIO continues to build its case as the best-in-class measure of the tumor microenvironment. We are making rapid progress on feasibility for a Research Use Only version of this test to support researchers who need a better tool to identify patients poised to respond to immunotherapies,” said Joshua Riggs, Oncocyte CEO. “And DetermaCNI is a blood-only solution for efficacy monitoring, which we believe will make it an attractive alternative for researchers that need to conserve precious tissue, since no upfront tumor typing is required.”

About Oncocyte

Oncocyte is a precision diagnostics company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. VitaGraft™ is a blood-based solid organ transplantation monitoring test, and pipeline test DetermaCNI™ is blood-based monitoring tool for assessing therapeutic efficacy in cancer. 

DetermaIO™, DetermaCNI™, and VitaGraft™ are trademarks of Oncocyte Corporation.

Forward-Looking Statements

Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, the expectation that there will be a Research Use Only version of DetermaIO to support researchers who need a better tool to identify patients poised to respond to immunotherapies, the expectation that DetermaCNI will be an attractive alternative for researchers that need to conserve precious tissue, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on Oncocyte or its subsidiaries’ financial and operational results, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte’s third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact
Jesse Arno
(949) 409-6770
jarno@oncocyte.com  

FAQ

What is the significance of Oncocyte's research presentations at the American Association for Cancer Research?

Oncocyte presented five original research posters, emphasizing the role of tumor microenvironment in therapy responses and showcasing their proprietary tests.

What does DetermaIO do?

DetermaIO is a gene expression test that assesses the tumor microenvironment to predict a patient's response to immunotherapies.

How does DetermaCNI support cancer treatment monitoring?

DetermaCNI is a blood-based test that monitors therapeutic efficacy, particularly in metastatic pancreatic cancer, without the need for upfront tumor typing.

Who is the CEO of Oncocyte Corporation?

Joshua Riggs is the CEO of Oncocyte Corporation.

What are the risks mentioned in Oncocyte's press release?

The release includes forward-looking statements detailing risks such as potential impacts from COVID-19 and uncertainties in regulatory approvals.